P&L Statement
$/procedure: primary ablation (36475 RFA · 36482 VenaSeal · 36465/36466 Varithena) + ultrasound allocation (93970/93971) + liquid sclero allocation (36470/36471).
Buffers: E&M revenue (99203/99204/99213/99214) excluded; final Gross / Net / EBITDA reflect a 10% conservatism haircut.
Monthly P&L Waterfall
Monthly P&L Detail
| Line Item | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Revenue | $61,372 | $69,087 | $77,081 | $98,189 | $129,018 | $155,258 | $181,500 | $188,060 | $188,060 | $188,060 | $188,060 | $188,060 | $1,711,805 |
| Management Fee | ($5,455) | ($6,141) | ($6,852) | ($8,728) | ($11,468) | ($13,801) | ($16,133) | ($16,716) | ($16,716) | ($16,716) | ($16,716) | ($16,716) | ($152,158) |
| Net Revenue | $56,462 | $63,560 | $70,914 | $90,334 | $118,697 | $142,837 | $166,981 | $173,015 | $173,015 | $173,015 | $173,015 | $173,015 | $1,574,860 |
| Total COGS | $11,299 | $12,392 | $13,485 | $16,764 | $21,503 | $25,877 | $30,251 | $31,342 | $31,342 | $31,342 | $31,342 | $31,342 | $288,281 |
| Gross Profit | $46,293 | $52,407 | $58,777 | $75,246 | $99,344 | $119,548 | $139,755 | $144,807 | $144,807 | $144,807 | $144,807 | $144,807 | $1,315,405 |
| Total OpEx | $65,957 | $66,628 | $67,306 | $68,775 | $70,960 | $73,043 | $75,126 | $77,272 | $79,272 | $87,272 | $89,272 | $91,272 | $912,155 |
| EBITDA | ($13,068) | ($7,558) | ($1,798) | $13,349 | $35,480 | $53,809 | $72,141 | $75,263 | $73,463 | $66,263 | $64,463 | $62,663 | $494,470 |
| EBITDA Margin | -23.1% | -11.9% | -2.5% | 14.8% | 29.9% | 37.7% | 43.2% | 43.5% | 42.5% | 38.3% | 37.3% | 36.2% | 31.4% |